MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
一项以微小残留病灶(MRD)为导向的2期临床研究,评估达雷妥尤单抗、卡非佐米、来那度胺和地塞米松联合治疗新诊断多发性骨髓瘤的疗效
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2024014417
Bhutani, Manisha; Robinson, Myra; Foureau, David; Atrash, Shebli; Paul, Barry; Guo, Fei; Grayson, Jason M; Ivanina-Foureau, Anna; Pineda-Roman, Mauricio; Varga, Cindy; Friend, Reed; Ferreri, Christopher J; Begic, Xhevahire; Norek, Sarah; Drennan, Tiffany; Anderson, Michelle B; Symanowski, James T; Voorhees, Peter M; Usmani, Saad Z